Current evidence and practical guidance for the use of sodium–glucose cotransporter-2 inhibitors in type 2 diabetes

Aakansha Zala, Louise J. Maple-Brown, Jonathan E. Shaw, Matthew J.L. Hare

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background The burden of type 2 diabetes (T2D) and its associated complications continues to grow in Australia. In recent years, sodium–glucose co-transporter-2 (SGLT2) inhibitors have become a key component of diabetes care with rapid uptake into routine clinical practice. There is growing evidence of their clinical efficacy, but also potential adverse effects. 

Objective The aim of this article is to review the use of SGLT2 inhibitors in T2D by exploring data surrounding clinical efficacy and safety as well as providing practical advice for prescribing clinicians. 

Discussion SGLT2 inhibitors have multiple metabolic benefits including reducing glycated haemoglobin, weight and blood pressure. Additionally, there are strong cardiovascular benefits and renoprotective effects in selected populations. Current evidence suggests that SGLT2 inhibitors should be considered for the secondary prevention of cardiovascular disease and to delay progression of early chronic kidney disease in people with T2D. Clinicians should also be aware of common side effects and potential rare severe complications.

Original languageEnglish
Pages (from-to)225-230
Number of pages6
JournalAustralian journal of general practice
Volume50
Issue number4
DOIs
Publication statusPublished - Apr 2021

Fingerprint

Dive into the research topics of 'Current evidence and practical guidance for the use of sodium–glucose cotransporter-2 inhibitors in type 2 diabetes'. Together they form a unique fingerprint.

Cite this